SanegeneBio Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$110M
- Investors
-
25
SanegeneBio General Information
Description
Developer of RNA interference therapeutics designed to treat diseases with significant unmet medical needs. The company offers therapeutics based on proprietary N-acetylgalactosamine and extrahepatic delivery platforms, enabling healthcare providers to address autoimmune, cardiovascular, metabolic, obesity and coagulation-related diseases.
Contact Information
Website
www.sanegenebio.comCorporate Office
- Room 301, Building 2, Area B
- Phase III Project
- Suzhou, Jiangsu 215000
- China
Corporate Office
- Room 301, Building 2, Area B
- Phase III Project
- Suzhou, Jiangsu 215000
- China
SanegeneBio Timeline
SanegeneBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series B) | 20-Nov-2025 | $110M | Completed | Clinical Trials - Phase 2 | ||
| 4. Early Stage VC (Series A1) | 30-Sep-2024 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 01-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 07-Feb-2021 | $12M | $12M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
SanegeneBio Patents
SanegeneBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260357263-A1 | Small interfering rna targeting lp(a) and uses thereof | Pending | 29-Nov-2023 | ||
| US-20240309383-A1 | Small interfering rna targeting hbv and uses thereof | Pending | 24-Feb-2023 | ||
| WO-2024175111-A2 | Small interfering rna targeting hbv and uses thereof | Inactive | 24-Feb-2023 | ||
| WO-2024175111-A3 | Small interfering rna targeting hbv and uses thereof | Inactive | 24-Feb-2023 | C12N15/1131 |
SanegeneBio Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hillhouse Capital | PE/Buyout | Minority | ||
| Invus (Private Equity) | PE/Buyout | Minority | ||
| Lake Bleu Capital | Hedge Fund | Minority | ||
| Legend Capital | Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority |
SanegeneBio FAQs
-
When was SanegeneBio founded?
SanegeneBio was founded in 2021.
-
Where is SanegeneBio headquartered?
SanegeneBio is headquartered in Suzhou, China.
-
What industry is SanegeneBio in?
SanegeneBio’s primary industry is Drug Discovery.
-
Is SanegeneBio a private or public company?
SanegeneBio is a Private company.
-
What is SanegeneBio’s current revenue?
The current revenue for SanegeneBio is .
-
How much funding has SanegeneBio raised over time?
SanegeneBio has raised $247M.
-
Who are SanegeneBio’s investors?
Hillhouse Capital, Invus (Private Equity), Lake Bleu Capital, Legend Capital, and Lilly USA are 5 of 25 investors who have invested in SanegeneBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process